Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes

A multiple antigen peptide (MAP) malaria vaccine containing minimal Plasmodium falciparum circumsporozoite protein repeat epitopes was assessed for safety and immunogenicity in volunteers of known class II genotypes. The MAP/alum/QS-21 vaccine formulation elicited high levels of parasite-specific an...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 182; no. 5; pp. 1486 - 1496
Main Authors: Nardin, Elizabeth H., Oliveira, Giane A., Calvo-Calle, J. Mauricio, Castro, Z. Rosa, Nussenzweig, Ruth S., Schmeckpeper, Barbara, Hall, B. Fenton, Diggs, Carter, Bodison, Sacared, Edelman, Robert
Format: Journal Article
Language:English
Published: Chicago, IL The University of Chicago Press 01-11-2000
University of Chicago Press
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A multiple antigen peptide (MAP) malaria vaccine containing minimal Plasmodium falciparum circumsporozoite protein repeat epitopes was assessed for safety and immunogenicity in volunteers of known class II genotypes. The MAP/alum/QS-21 vaccine formulation elicited high levels of parasite-specific antibodies in 10 of 12 volunteers expressing DQB1*0603, DRB1*0401, or DRB1*1101 class II molecules. In contrast, volunteers of other HLA genotypes were low responders or nonresponders. A second study of 7 volunteers confirmed the correlation of class II genotype and high responder phenotype. This is the first demonstration in humans that a peptide vaccine containing minimal T and B cell epitopes composed of only 5 amino acids (N, A, V, D, and P) can elicit antibody titers comparable to multiple exposures to irradiated P. falciparum—infected mosquitoes. Moreover, the high-responder phenotypes were predicted by analysis of peptide/HLA interactions in vitro, thus facilitating the rational design of epitope-based peptide vaccines for malaria, as well as for other pathogens.
Bibliography:istex:F393E8B90CDC33E6CECCF558A05D500FB51EE8AD
ark:/67375/HXZ-4QR6LBXQ-K
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/315871